Novartis Announces EC Approvals for Cosentyx to Treat Patients with Ankylosing Spondylitis, Psoriatic Arthritis

by Charles Gross, Benzinga Editor

November 23, 2015 4:12 AM | 16 seconds read | Make a Comment

Novartis

NVS

announced today that the European Commission (EC) has approved Cosentyx® (secukinumab) for the treatment of people living with ankylosing spondylitis (AS) and psoriatic arthritis (PsA). For AS, this is the first new treatment advance in 16 years since the development of the

See full press release

Market News and Data brought to you by Benzinga APIs

Posted In: News Press Releases

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!